No Data
China Merchants: Class B catalog will be released within the year + Commercial health Insurance provides additional payment for Innovative Drugs, further improving bulk purchasing and medical insurance prepayment.
The first version of the Category B directory is scheduled to be released within this year, and it is expected to be aligned with the annual adjustments of the medical insurance directory, contributing to the incremental increase of payments for Innovative Drugs.
Huahai Pharmaceutical Gets US FDA Approval to Conduct Trials for Asthma Treatment; Shares Down 4%
Potential Upside For Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) Not Without Risk
Kent Catalysts submitted a registration for an IPO to the Shanghai Stock Exchange, focusing on the field of phase transfer catalysts.
On January 13, Kent Catalytic Materials Co., Ltd. (abbreviated as Kent Catalytic) applied to change its IPO review status on the Shanghai Stock Exchange Main Board to "submitted for registration." Sinolink is its sponsoring institution, aiming to raise 0.499 billion yuan.
Zhejiang Huahai Pharmaceutical Gets China Nod for Hypertension Drug
Zhejiang Huahai Pharmaceutical (600521.SH): Tamsulosin tablets have obtained the Pharmaceutical registration certificate.
On January 9, the company Zhejiang Huahai Pharmaceutical (600521.SH) announced that it recently received the "Pharmaceutical Registration Certificate" for Telmisartan tablets issued by the National Medical Products Administration. Telmisartan tablets are used to treat hypertension and reduce cardiovascular risk.
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects
No Data
